CWM
ALDX icon

Curi Wealth Management’s Aldeyra Therapeutics ALDX Stock Holding History

Curi Wealth Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-21,500
Closed -$115K – 188
2022
Q3 		$115K Buy
+21,500
New +$129K 0.02% 181

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Curi Wealth Management's ALDX Position: Q4 2022 in Review

Curi Wealth Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2022, closing a stake of 21,500 shares — an estimated $115K sold.

Curi Wealth Management first reported a position in ALDX in Q3 2022 and held it in 1 quarter. The position peaked at $115K in Q3 2022. 96 funds tracked by Wall St. Rank hold ALDX as of Q4 2022.

  • Curi Wealth Management reported no remaining Aldeyra Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Curi Wealth Management sold 21,500 Aldeyra Therapeutics shares in Q4 2022, an estimated $115K.
  • Curi Wealth Management first reported a position in Aldeyra Therapeutics in Q3 2022 and held it in 1 quarter.
  • Curi Wealth Management's Aldeyra Therapeutics position peaked at $115K in Q3 2022.
  • 96 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2022.

Based on Curi Wealth Management's 13F filing for Q4 2022, filed 3 Feb 2023.